File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/ijc.23634
- Scopus: eid_2-s2.0-47249149299
- PMID: 18553387
- WOS: WOS:000258243300008
- Find via
Supplementary
-
Bookmarks:
- CiteULike: 1
- Citations:
- Appears in Collections:
Article: Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells
Title | Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells |
---|---|
Authors | |
Keywords | c-Jun Endothelial cells HCC Hepatocellular carcinoma cells Hypermethylation LOH T-cadherin Underexpression |
Issue Date | 2008 |
Publisher | John Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home |
Citation | International Journal Of Cancer, 2008, v. 123 n. 5, p. 1043-1052 How to Cite? |
Abstract | T-cadherin is an atypical cadherin and growing evidence has indicated that T-cadherin exerts tumor-suppressive effects on cancers of epithelial cell type and also causes positive effects on tumor angiogenesis. Human hepatocellular carcinoma (HCC) is a hypervascular tumor and T-cadherin has been shown to be overexpressed in intratumoral endothelial cells of HCCs. However, the expression status and functions of T-cadherin in hepatocytes or HCC cells remain unclear. Here, we demonstrated that T-cadherin was underexpressed in HCC cells (26.5%, 13/49 cases), but was frequently (77.6%, 38/49) overexpressed in intratumoral endothelial cells immunohistochemically. Semiquantitative RT-PCR analysis also showed that the T-cadherin gene was underexpressed in 7 of 11 HCC cell lines. Loss of heterozygosity analysis revealed that 32-38% of the 42 human HCC samples had allelic losses at this locus. Upon pharmacological treatment with demethylating agent 5-aza-2′-deoxycytidine or histone deacetylase inhibitor trichostatin A, T-cadherin promoter hypermethylation and/or histone deacetylation was frequently observed in HCC samples and cell lines. Functionally, enforced expression of T-cadherin induced G2/M cell cycle arrest, reduced cell proliferation in low serum medium, suppressed anchorage-independent growth in soft agar and increased sensitivity to TNFα-mediated apoptosis in HCC cells. Intriguingly, we found that T-cadherin significantly suppressed the activity of c-Jun, a crucial oncoprotein constitutively activated in HCC cells. To conclude, T-cadherin was differentially expressed in human HCCs. The underexpression of T-cadherin in HCC cells suggests it may be another critical event in addition to T-cadherin-mediated angiogenesis during HCC development. © 2006 Wiley-Liss, Inc. |
Persistent Identifier | http://hdl.handle.net/10722/60586 |
ISSN | 2023 Impact Factor: 5.7 2023 SCImago Journal Rankings: 2.131 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, DW | en_HK |
dc.contributor.author | Lee, JMF | en_HK |
dc.contributor.author | Chan, PCY | en_HK |
dc.contributor.author | Ng, IOL | en_HK |
dc.date.accessioned | 2010-05-31T04:14:13Z | - |
dc.date.available | 2010-05-31T04:14:13Z | - |
dc.date.issued | 2008 | en_HK |
dc.identifier.citation | International Journal Of Cancer, 2008, v. 123 n. 5, p. 1043-1052 | en_HK |
dc.identifier.issn | 0020-7136 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/60586 | - |
dc.description.abstract | T-cadherin is an atypical cadherin and growing evidence has indicated that T-cadherin exerts tumor-suppressive effects on cancers of epithelial cell type and also causes positive effects on tumor angiogenesis. Human hepatocellular carcinoma (HCC) is a hypervascular tumor and T-cadherin has been shown to be overexpressed in intratumoral endothelial cells of HCCs. However, the expression status and functions of T-cadherin in hepatocytes or HCC cells remain unclear. Here, we demonstrated that T-cadherin was underexpressed in HCC cells (26.5%, 13/49 cases), but was frequently (77.6%, 38/49) overexpressed in intratumoral endothelial cells immunohistochemically. Semiquantitative RT-PCR analysis also showed that the T-cadherin gene was underexpressed in 7 of 11 HCC cell lines. Loss of heterozygosity analysis revealed that 32-38% of the 42 human HCC samples had allelic losses at this locus. Upon pharmacological treatment with demethylating agent 5-aza-2′-deoxycytidine or histone deacetylase inhibitor trichostatin A, T-cadherin promoter hypermethylation and/or histone deacetylation was frequently observed in HCC samples and cell lines. Functionally, enforced expression of T-cadherin induced G2/M cell cycle arrest, reduced cell proliferation in low serum medium, suppressed anchorage-independent growth in soft agar and increased sensitivity to TNFα-mediated apoptosis in HCC cells. Intriguingly, we found that T-cadherin significantly suppressed the activity of c-Jun, a crucial oncoprotein constitutively activated in HCC cells. To conclude, T-cadherin was differentially expressed in human HCCs. The underexpression of T-cadherin in HCC cells suggests it may be another critical event in addition to T-cadherin-mediated angiogenesis during HCC development. © 2006 Wiley-Liss, Inc. | en_HK |
dc.language | eng | en_HK |
dc.publisher | John Wiley & Sons, Inc.. The Journal's web site is located at http://www3.interscience.wiley.com/journal/29331/home | en_HK |
dc.relation.ispartof | International Journal of Cancer | en_HK |
dc.rights | International Journal of Cancer. Copyright © John Wiley & Sons, Inc. | en_HK |
dc.subject | c-Jun | en_HK |
dc.subject | Endothelial cells | en_HK |
dc.subject | HCC | en_HK |
dc.subject | Hepatocellular carcinoma cells | en_HK |
dc.subject | Hypermethylation | en_HK |
dc.subject | LOH | en_HK |
dc.subject | T-cadherin | en_HK |
dc.subject | Underexpression | en_HK |
dc.subject.mesh | Acetylation - drug effects | en_HK |
dc.subject.mesh | Adult | en_HK |
dc.subject.mesh | Aged | en_HK |
dc.subject.mesh | Anticarcinogenic Agents - metabolism | en_HK |
dc.subject.mesh | Antimetabolites, Antineoplastic - pharmacology | en_HK |
dc.subject.mesh | Apoptosis - drug effects | en_HK |
dc.subject.mesh | Azacitidine - analogs & derivatives - pharmacology | en_HK |
dc.subject.mesh | Blotting, Western | en_HK |
dc.subject.mesh | Cadherins - drug effects - genetics - metabolism | en_HK |
dc.subject.mesh | Carcinoma, Hepatocellular - drug therapy - genetics - metabolism | en_HK |
dc.subject.mesh | Cell Cycle - drug effects | en_HK |
dc.subject.mesh | Cell Proliferation - drug effects | en_HK |
dc.subject.mesh | DNA Methylation - drug effects | en_HK |
dc.subject.mesh | DNA Modification Methylases - antagonists & inhibitors | en_HK |
dc.subject.mesh | Down-Regulation | en_HK |
dc.subject.mesh | Epigenesis, Genetic - drug effects | en_HK |
dc.subject.mesh | Female | en_HK |
dc.subject.mesh | Gene Expression Regulation, Neoplastic - drug effects | en_HK |
dc.subject.mesh | Gene Silencing - drug effects | en_HK |
dc.subject.mesh | Histone Deacetylase Inhibitors | en_HK |
dc.subject.mesh | Histones - metabolism | en_HK |
dc.subject.mesh | Humans | en_HK |
dc.subject.mesh | Hydroxamic Acids - pharmacology | en_HK |
dc.subject.mesh | Immunohistochemistry | en_HK |
dc.subject.mesh | Liver Neoplasms - drug therapy - genetics - metabolism | en_HK |
dc.subject.mesh | Loss of Heterozygosity | en_HK |
dc.subject.mesh | Male | en_HK |
dc.subject.mesh | Middle Aged | en_HK |
dc.subject.mesh | Promoter Regions, Genetic | en_HK |
dc.subject.mesh | Proto-Oncogene Proteins c-jun - drug effects - metabolism | en_HK |
dc.subject.mesh | Reverse Transcriptase Polymerase Chain Reaction | en_HK |
dc.subject.mesh | Up-Regulation | en_HK |
dc.title | Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells | en_HK |
dc.type | Article | en_HK |
dc.identifier.openurl | http://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0020-7136&volume=123&spage=1043&epage=1052&date=2008&atitle=Genetic+and+epigenetic+inactivation+of+T-cadherin+in+human+hepatocellular+carcinoma+cells | en_HK |
dc.identifier.email | Chan, DW:dwchan@hkucc.hku.hk | en_HK |
dc.identifier.email | Ng, IOL:iolng@hkucc.hku.hk | en_HK |
dc.identifier.authority | Chan, DW=rp00543 | en_HK |
dc.identifier.authority | Ng, IOL=rp00335 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1002/ijc.23634 | en_HK |
dc.identifier.pmid | 18553387 | - |
dc.identifier.scopus | eid_2-s2.0-47249149299 | en_HK |
dc.identifier.hkuros | 145621 | en_HK |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-47249149299&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 123 | en_HK |
dc.identifier.issue | 5 | en_HK |
dc.identifier.spage | 1043 | en_HK |
dc.identifier.epage | 1052 | en_HK |
dc.identifier.isi | WOS:000258243300008 | - |
dc.publisher.place | United States | en_HK |
dc.identifier.scopusauthorid | Chan, DW=26533900600 | en_HK |
dc.identifier.scopusauthorid | Lee, JMF=36065603500 | en_HK |
dc.identifier.scopusauthorid | Chan, PCY=24491622600 | en_HK |
dc.identifier.scopusauthorid | Ng, IOL=7102753722 | en_HK |
dc.identifier.citeulike | 3167977 | - |
dc.identifier.issnl | 0020-7136 | - |